American Cancer Society, Trial Library, and the PCCTC Collaborate to Support Recruitment of Black Patients for Clinical Trials
The American Cancer Society announced a new collaboration with Trial Library, Inc., and the PCCTC to support a national initiative to accelerate the recruitment of Black patients to prostate cancer clinical trials.
PCCTC Investigator Dr. Rana McKay Wins the 2024 Christopher G. Wood Rising Star Award at IKCS Europe
Dr McKay won the 2024 Christopher G. Wood Rising Star Award at IKCS Europe, which took place in Sitges, Spain between April 18th and 20th, 2024.
OncoC4 Announces First Patient with Advanced Prostate Cancer Dosed in Phase 1/2 Trial of BioNTech-partnered BNT316/ONC-392 Program
OncoC4, Inc. (“OncoC4”) today announced that the first patient with metastatic castration resistant prostate cancer has been dosed in a PCCTC-managed Phase 1/2 trial evaluating the anti-CTLA-4 antibody candidate BNT316/ONC-392 (gotistobart) in combination with radioligand therapy, lutetium (177Lu) vipivotide tetraxetan (Pluvicto®).
The PCCTC-managed IRONMAN Registry Deepens the Understanding of Racial Disparities in Pain and Survival in Individuals with Advanced Prostate Cancer
Manuscript published in Cancer Research Communications finds Black participants with advanced prostate cancer reported worse pain than White participants, and more pain was associated with worse survival. More holistic clinical assessments of pain in this population are needed to determine the factors upon which to intervene to improve quality of life and survivorship, particularly for Black individuals.
The PCCTC-managed PROMISE Registry Manuscript Published In The Prostate.
The PROMISE Registry aims to provide access to germline genetic testing and to collect data to understand disease characteristics and treatment responses across the disease spectrum for prostate cancer with rare germline genetic variants.
PCCTC Scientific Oversight Committee Chair Reflects on Advances Made in High-Risk, Low-Grade Prostate Cancer Management
Howard I. Scher, MD, sheds light on various research programs he has led or has been heavily involved with that have helped change the course of prostate cancer treatment over the years.
Results from the PCCTC's STREAM Study Led by Rhonda L Bitting, MD of Duke University Published
Study shows that LD and higher ADT sensitivity tumors had favorable outcomes. Those with a luminal proliferating subtype, PTEN loss, and/or HRD signatures had poor outcomes despite ADT/radiation and enzalutamide and may benefit from alternative approach.
Results from the PCCTC’s Randomized Phase 2 Trial of Abiraterone Acetate With or Without Cabazitaxel Published in The Journal of Clinical Oncology
Combination was safe with improved rPFS, OS duration, and a higher proportion ofPSA declines.
Caris Life Sciences, PCCTC, and Sorrento Therapeutics Announce Collaboration to Advance Precision Medicine Development Using Comprehensive Genomic Profiling
Caris Life Sciences®, the Prostate Cancer Clinical Trial Consortium and Sorrento Therapeutics, Inc. announced a strategic collaboration to guide more precise treatment decisions for patients with advanced prostate cancer.
Lantheus Collaborates with The PCCTC To Advance AI-Enabled Imaging Biomarkers in Prostate Cancer
Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus) announced that its subsidiary, EXINI Diagnostics AB (EXINI), has entered into a collaboration with the Prostate Cancer Clinical Trials Consortium (PCCTC) to advance artificial intelligence (AI)-enabled imaging biomarkers in prostate cancer.